Article
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.
International journal of oncology - 1 Jan 2014
Bruera Gemma, Cannita Katia, Giordano Aldo Victor, Vicentini Roberto, Ficorella Corrado, Ricevuto Enrico
Abstract excerpt
Clinical outcome post-progression to first-line triplet chemotherapy (CT) plus bevacizumab (FIr-B/FOx) was evaluated in metastatic colorectal cancer (MCRC) patients (pts). Second-line treatment was selected according to fitness, KRAS genotype, previous efficacy and safety. Efficacy was evaluated and compared according to treatment or KRAS genotype, using log-rank analysis. Among 54 pts, median overall survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.